{"id":"NCT02459795","sponsor":"Padagis LLC","briefTitle":"To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2015-06-02","resultsPosted":"2021-01-22","lastUpdate":"2021-11-02"},"enrollment":469,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"Ingenol Mebutate (Perrigo)","otherNames":["Perrigo product"]},{"type":"DRUG","name":"Ingenol Mebutate (Reference)","otherNames":["Reference Listed Drug Product"]},{"type":"DRUG","name":"Placebo gel","otherNames":["placebo"]}],"arms":[{"label":"Test product","type":"EXPERIMENTAL"},{"label":"Reference product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo product","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare safety and efficacy of Perrigo's drug compared to an FDA approved drug in the treatment of actinic keratosis.","primaryOutcome":{"measure":"Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions","timeFrame":"Baseline to Day 57","effectByArm":[{"arm":"Test Product","deltaMin":71,"sd":null},{"arm":"Reference Product","deltaMin":71,"sd":null},{"arm":"Placebo Product","deltaMin":9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":187},"commonTop":["Application site Pruritus","Application site pain","Headache"]}}